| Literature DB >> 32227466 |
Li Wang1, Ying Xing1, Xinwen Yu1, Jie Ming1, Xiangyang Liu1, Xiaomiao Li1, Jianfang Fu1, Jie Zhou1, Bin Gao1, Dayi Hu2, Changyu Pan3, Linong Ji4, Qiuhe Ji1.
Abstract
AIMS/Entities:
Keywords: Macrovascular complication; Microvascular complication; Type 2 diabetes
Mesh:
Year: 2020 PMID: 32227466 PMCID: PMC7477533 DOI: 10.1111/jdi.13262
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Comparison of diabetes patient characteristics between northern and southern China
| Total | Northern | Southern | χ2/ |
| |
|---|---|---|---|---|---|
|
| 25,398 | 11,932 (47.0) | 13,466 (53.0) | ||
| Hospital level, | |||||
| Primary | 6,513 (25.6) | 3,061 (25.7) | 3,452 (25.6) | 2.982 | 0.225 |
| Secondary | 9,444 (37.2) | 4,377 (36.7) | 5,067 (37.6) | ||
| Tertiary | 9,441 (37.2) | 4,494 (37.7) | 4,947 (36.7) | ||
| Age (years) | 62.6 ± 11.91 | 61.64 ± 11.88 | 63.45 ± 11.87 | 12.109 | <0.001 |
| Age group, | |||||
| ≥65 | 11,565 (45.5) | 5,056 (42.4) | 6,509 (48.3) | 90.706 | <0.001 |
| Sex, | |||||
| Male | 11,944 (47.0) | 5,807 (48.7) | 6,137 (45.6) | 24.301 | <0.001 |
| Ethnicity, | |||||
| Han | 24,943 (98.2) | 11,609 (97.3) | 13,334 (99.0) | 107.215 | <0.001 |
| Age at diabetes diagnosis (years) | 54.55 ± 11.86 | 53.56 ± 11.86 | 55.43 ± 11.79 | 12.616 | <0.001 |
| Diabetes duration (years) | 6 (2–11) | 6 (2–11) | 6 (2–11) | 1.102 | 0.27 |
| Weight (kg) | 65 (59–74) | 69 (60–76) | 63 (55–70) | 11.271 | <0.001 |
| BMI (kg/m2) | 24.61 (22.52–26.84) | 25.08 (23.03–27.34) | 24.17 (22.06–26.37) | 6.432 | <0.001 |
| SBP (mmHg) | 133 ± 16.34 | 133.58 ± 16.03 | 132.48 ± 16.59 | 5.347 | <0.001 |
| DBP (mmHg) | 78.77 ± 10.08 | 79.97 ± 9.05 | 77.71 ± 10.8 | 18.017 | <0.001 |
| TC (mmol/L) | 4.97 ± 1.45 | 4.99 ± 1.28 | 4.95 ± 1.59 | 2.093 | 0.036 |
| LDL‐C (mmol/L) | 2.83 ± 1 | 2.86 ± 0.97 | 2.8 ± 1.03 | 4.807 | <0.001 |
| HDL‐C (mmol/L) | 1.3 ± 0.48 | 1.31 ± 0.52 | 1.3 ± 0.44 | 1.638 | 0.101 |
| TG (mmol/L) | 1.56 (1.1–2.27) | 1.61 (1.13–2.33) | 1.5 (1.06–2.22) | 8.995 | <0.001 |
| HbA1c (%) | 7.65 ± 2.05 | 7.8 ± 2.04 | 7.51 ± 2.06 | 11.307 | <0.001 |
|
| 4,168 (16.4) | 2,183 (18.3) | 1,985 (14.7) | 58.268 | <0.001 |
|
| 2,019 (8.0) | 1,147 (9.6) | 872 (6.5) | 85.091 | <0.001 |
| Exercise, | |||||
| No | 11,069 (43.6) | 4,865 (40.8) | 6,204 (46.1) | 72.243 | <0.001 |
| Frequent/PRN | 14,329 (56.4) | 7,067 (59.2) | 7,262 (53.9) | ||
| Education, | |||||
| Illiteracy | 1,679 (6.6) | 575 (4.8) | 1,104 (8.2) | 549.791 | <0.001 |
| Elementary school | 5,649 (22.2) | 2,071 (17.4) | 3,578 (26.6) | ||
| Middle school | 11,907 (46.9) | 5,918 (49.6) | 5,989 (44.5) | ||
| High school | 3,929 (15.5) | 2,067 (17.3) | 1,862 (13.8) | ||
| College level | 2,234 (8.8) | 1,301 (10.9) | 933 (6.9) | ||
| Income, | |||||
| Low | 14,811 (58.3) | 6,555 (54.9) | 8,256 (61.3) | 344.011 | <0.001 |
| Medium | 8,775 (34.6) | 4,726 (39.6) | 4,049 (30.1) | ||
| High | 1,096 (4.3) | 463 (3.9) | 633 (4.7) | ||
| Blood pressure control achieved, | 18,801 (74.0) | 8,630 (72.3) | 10,171 (75.5) | 33.786 | <0.001 |
| Lipid control achieved, | 10,938 (43.1) | 4,937 (41.4) | 6,001 (44.6) | 26.222 | <0.001 |
| Glucose level control achieved, | 11,322 (44.6) | 4,877 (40.9) | 6,445 (47.9) | 125.042 | <0.001 |
| Glucose level/lipid/blood pressure control achieved, | 4,051 (16.0) | 1,664 (14.0) | 2,387 (17.7) | 67.443 | <0.001 |
Data are the mean (standard deviation), median (interquartile range) or n (%); t is the t‐value of two independent sample t‐tests, χ2 is the χ2 value of Pearson’s χ2‐test, Z is the Z‐value of the Mann–Whitney U‐test.
Includes previous smoking or drinking history (non‐smoker, ex‐smoker, 1–5 cigarettes per day or ≥6 cigarettes per day; and non‐drinker, ex‐drinker, 1–10 g alcohol per day or ≥11 g alcohol per day). Targets of glycemic control were defined as glycated hemoglobin (HbA1c) of <7% whether patients were taking oral antidiabetic drugs or insulin or not. Targets of blood pressure control were defined as systolic blood pressure (SBP)/diastolic blood pressure (DBP) <140/90 mmHg whether patients were taking antihypertensive drugs or not. Targets of lipid control were defined as total cholesterol (TC) <4.5 mmol/L and low‐density lipoprotein cholesterol (LDL‐C) <2.6 mmol/L whether patients were taking lipid‐lowering drugs or not. BMI, body mass index; PRN, three times/week; TG, triglycerides.
Figure 1Combined control of risk factors between northern and southern China stratified by age. (a) For achieved low‐density lipoprotein cholesterol control: P = 0.668 for the group aged <35 years, P = 0.777 for the group aged 35–44 years, P = 0.012 for the group aged 45–54 years, P = 0.117 for the group aged 55–64 years, P = 0.007 for the group aged 65–74 years and P < 0.001 for the group aged >75 years. (b) For achieved blood pressure control: P = 0.691 for the group aged <35 years, P = 0.018 for the group aged 35–44 years, P < 0.001 for the group aged 45–54 years, P < 0.001 for the group aged 55–64 years, P = 0.007 for the group aged 65–74 years and P = 0.001 for the group aged >75 years. (c) For achieved glycated hemoglobin control: P = 0.009 for the group aged <35, P = 0.007 for the group aged 35–44 years, P < 0.001 for the group aged 45–54 years, P < 0.001 for the group aged 55–64 years, P < 0.001 for the group aged 65–74 years and P = 0.005 for the group aged >75 years. (d) For achieving all of the 3B target goals: P = 0.151 for the group aged <35 years, P = 0.009 for the group aged 35–44 years, P < 0.001 for the group aged 45–54 years, P < 0.001 for the group aged 55–64 years, P = 0.014 for the group aged 65–74 years and P = 0.009 for the group aged >75 years.
Comorbidities and complications of diabetes patients between northern and southern China
| Total | Northern | Southern | χ2 |
| |
|---|---|---|---|---|---|
|
| 25,398 | 11,932 | 13,466 | ||
| Comorbidities | 445.545 | <0.001 | |||
| Hypertension only | 8,732 (34.4) | 3,676 (30.8) | 5,056 (37.6) | ||
| Dyslipidemia only | 2,790 (11.0) | 1,514 (12.7) | 1,276 (9.5) | ||
| Hypertension and dyslipidemia complication | 5,659 (22.3) | 3,240 (27.2) | 2,419 (18.0) | ||
| CVD | 4,111 (16.2) | 2,504 (21.0) | 1,607 (11.9) | 382.087 | <0.001 |
| CBD | 2,202 (8.7) | 1,157 (9.7) | 1,045 (7.8) | 29.956 | <0.001 |
| PVD | 391 (1.5) | 162 (1.4) | 229 (1.7) | 4.907 | 0.027 |
| Macrovascular complications | 6,040 (23.8) | 3,419 (28.7) | 2,621 (19.5) | 294.784 | <0.001 |
| Nephropathy | 3,680 (14.5) | 1,839 (15.4) | 1,841 (13.7) | 15.474 | <0.001 |
| Retinopathy | 4,527 (17.8) | 2,168 (18.2) | 2,359 (17.5) | 1.833 | 0.176 |
| Neuropathy | 3,394 (13.4) | 1,815 (15.2) | 1,579 (11.7) | 66.380 | <0.001 |
| Microvascular complications | 9,364 (36.9) | 4,674 (39.2) | 4,690 (34.8) | 51.278 | <0.001 |
Comorbidities included hypertension only, dyslipidemia only and both conditions. Macrovascular complications included cardiovascular disease (CVD; including stable angina, unstable angina, myocardial infarction, percutaneous coronary intervention or underwent coronary bypass) cerebrovascular disease (CBD; including ischemic stroke, hemorrhagic stroke or transient ischemic attack) and peripheral vascular disease (PVD). Microvascular complications included nephropathy, retinopathy and neuropathy.
Figure 2Prevalence of diabetic complications between northern and southern China stratified by age. (a) For the prevalence of cardiovascular diseases: P = 0.382 for the group aged <35, P = 0.008 for the group aged 35–44 years and P < 0.001 for groups aged >45 years. (b) For the prevalence of ischemic stroke: P = 0.129 for the group aged <35 years, P = 0.147 for the group aged 35–44 years, P < 0.001 for the group aged 45–74 years and P = 0.418 for the group aged >75 years. (c) For the prevalence of macrovascular diseases: P = 0.869 for the group aged <35 years, P < 0.018 for the group aged 35–44 years and P < 0.001 for the groups aged >45 years. (d) For the prevalence of diabetic nephropathy: P = 0·800 for the group aged <35 years, P = 0.002 for the group aged 35–44 years, P < 0.001 for the group aged 45–54 years, P = 0.022 for the group aged 55–64 years, P = 0.056 for the group aged 65–74 years, and P = 0.983 for the group aged >75 years. (e) For the prevalence of diabetic retinopathy: P = 0.346 for the group aged <35 years, P = 0.581 for the group aged 35–44 years, P = 0.599 for the group aged 45–54 years, P = 0.628 for the group aged 55–64 years, P = 0.006 for the group aged 65–74 years and P < 0.001 for groups aged >75 years. (f) For the prevalence of diabetic neuropathy: P = 0.734 for the group aged <35 years, P = 0.116 for the group aged 35–44 years, P < 0.001 for the group aged 45–54 years, P < 0.001 for the group aged 55–64 years, P = 0.003 for the group aged 65–74 years and P = 0.696 for the group aged >75 years. *P < 0.05, **P < 0.01, ***P < 0.001.
Multifactor analysis of diabetic complications between northern and southern China
| Cardiovascular | Ischemic stroke | Nephropathy | Retinopathy | |||||
|---|---|---|---|---|---|---|---|---|
| 95% CI |
| 95% CI |
| 95% CI |
| 95% CI |
| |
| Model 1 | 2.188 (2.040–2.347) | <0.001 | 1.439 (1.312–1.578) | <0.001 | 1.177 (1.097–1.263) | <0.001 | 1.150 (1.076–1.229) | <0.001 |
| Model 2 | 2.173 (2.026–2.331) | <0.001 | 1.430 (1.304–1.569) | <0.001 | 1.168 (1.088–1.253) | <0.001 | 1.154 (1.079–1.233) | <0.001 |
| Model 3 | 2.166 (2.019–2.324) | <0.001 | 1.429 (1.302–1.567) | <0.001 | 1.165 (1.086–1.250) | <0.001 | 1.192 (1.114–1.277) | <0.001 |
| Model 4 | 2.174 (2.026–2.333) | <0.001 | 1.409 (1.283–1.547) | <0.001 | 1.129 (1.051–1.212) | <0.001 | 1.179 (1.101–1.263) | <0.001 |
| Model 5 | 2.171 (2.020–2.333) | <0.001 | 1.467 (1.332–1.616) | <0.001 | 1.133 (1.054–1.218) | <0.001 | 1.149 (1.072–1.232) | <0.001 |
| Model 6 | 2.211 (2.057–2.377) | <0.001 | 1.491 (1.353–1.644) | <0.001 | 1.149 (1.068–1.236) | <0.001 | 1.154 (1.076–1.237) | <0.001 |
Data are odds ratio (95% confidence interval [CI]). P‐value, northern compared with southern. The multivariable model was adjusted by different factors in the table. Multivariable model 1 was adjusted for age. Multivariable model 2 was adjusted for age, sex and ethnicity. Multivariable model 3 was adjusted for age, sex, ethnicity and weight. Multivariable model 4 was adjusted for age, sex, ethnicity, weight, blood pressure, low‐density lipoprotein cholesterol and glycated hemoglobin. Multivariable model 5 was adjusted for age, sex, ethnicity, weight, blood pressure, low‐density lipoprotein cholesterol, glycated hemoglobin, smoking, drinking, exercise education and income. Multivariable model 6 was adjusted for age, sex, ethnicity, weight, blood pressure, low‐density lipoprotein cholesterol, glycated hemoglobin, smoking, drinking, exercise, education, income and hospital.